Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
CWBR CohBar Inc
TSLA Tesla Inc
WEC WEC Energy Group Inc
PFE Pfizer Inc
T AT&T Inc
BFC Bank First Corp
RIGMF Ridgestone Mining Inc
BAC Bank of America Corp
WFC Wells Fargo & Co
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$76.35
Day's Change
0.29 (0.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
77.09
Day's Low
75.65
Volume
(Light)
Volume:
6,380,965

10-day average volume:
8,980,811
6,380,965

UPDATE: Tesla's stock has 'room to run' to $1,000, and possibly much higher, says Wedbush's Dan Ives

7:00 am ET June 10, 2020 (MarketWatch)
Print

Tesla Inc.'s stock (TSLA) has "room to run further" to $1,000 and possibly much higher, said Wedbush analyst Dan Ives, given his belief that demand in China for Model 3's are ramping stronger than expected and the potential for "game changing" battery developments. Ives reiterated his neutral rating on the electric car maker, but raised his base price target to $1,000 from $800, while boosting his "bull case" target to $1,500 from $1,350. The average price target of the 33 analysts surveyed by FactSet is $678.23. The stock, which eased 0.1% in premarket trading, lost 1.0% on Tuesday after closing at a record $949.92 on Monday. "We believe that the China growth story is worth at least $300 per share to Tesla as this EV penetration is set to ramp significantly over the next 12 to 18 months," Ives wrote in a note to clients. "Looking ahead, we believe [Chief Executive Elon Musk] are slated to announce a number of new potential "game changing" battery developments at its highly anticipated Battery Day." The battery day has been delayed given the COVID-19 pandemic, with some reports suggesting it could take place as a live event later this summer. The stock has more than doubled (up 124.9%) year to date through Tuesday, while the S&P 500 has lost 0.7%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

June 10, 2020 07:00 ET (11:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.